Novo Nordisk to continue largest insulin brand Mixtard supply in vials amid penfill device phase-out
Representative image
Novo Nordisk
has stated that its flagship
insulin
brand
Mixtard
will continue to be available in India in vial form, even as the company phases out other delivery formats such as
Penfill
cartridges, in a response to a Times of India report.
The announcement comes amid widespread concern over the discontinuation of some of the country's most-used insulin products.
Responding to reports that it was withdrawing Mixtard—India's top-selling insulin brand with annual sales of over Rs 800 crore—the Danish pharmaceutical giant reassured patients that the insulin, along with other human insulins like Actrapid and Insulatard, will still be accessible in vials across India.
These vials are administered through traditional syringes.
'In order to meet increasing patient demand and ensure a stable supply of our medicines, we have decided to consolidate our insulin portfolio. This will create space needed in our global manufacturing network,' Novo Nordisk said in a statement. 'Hence, in this process, we are phasing out the Penfill. We acknowledge that this will be disruptive to people living with diabetes who rely on our treatments.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Play this game for 3 minutes, if you own a mouse
planetcapture.io
Undo
However, by doing this now, we will increase the number of patients we reach with our insulin portfolio by many millions in the next decade.
'
This comes after reports that the Danish drugmaker was discontinuing Human Mixtard—India's largest-selling insulin brand—and other older-generation insulins from the market. The
TOI
report noted that Human Mixtard, a Rs 800 crore brand despite being under price control, along with products like Actrapid, Insulatard, Insulin Detemir, Levemir, and Xultophy, would no longer be available in popular delivery formats such as pre-filled pens and cartridges (Penfill and FlexPen).
Read report:
Novo Nordisk to phase out country's largest insulin brand
According to documents cited in the earlier report, Novo Nordisk had informed its marketing partner Abbott India that the products would be withdrawn once current stocks were exhausted, a process expected to take around six months. The move is reportedly part of the company's global strategy to shift focus toward newer, more profitable treatments such as
Ozempic
and
Wegovy
, which it plans to introduce in the Indian market this year. As part of this shift, earlier-generation insulin products are being gradually phased out worldwide.
Stay informed with the latest
business
news, updates on
bank holidays
and
public holidays
.
Master Value & Valuation with ET! Learn to invest smartly & decode financials. Limited seats at 33% off – Enroll now!
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Rekha throws open waiting hall at AIIMS for attendants
New Delhi: Chief minister Rekha Gupta on Thursday inaugurated a waiting hall for the attendants of patients at All India Institute of Medical Sciences. Gupta said govt and society needed to work together for a developed country and a developed Delhi. Tired of too many ads? go ad free now "I always say that govt and society need to come on one platform and work together, and only then will the goal of Viksit Bharat and Viksit Delhi be realised," CM said. Built for Rs 6 crore by Dhanuka Agritech Ltd as part of its corporate social responsibility initiative, the waiting hall will serve thousands of people. Spanning 68,800 square feet, the waiting area is fully air-conditioned, equipped with clean sanitation facilities, mobile charging stations and seating space for 1,500. Gupta also appreciated AIIMS, saying it was a ray of hope for millions of people in the country who come to the premier institute for the best treatment and life-saving medical interventions. She mentioned that AIIMS served more than six lakh patients annually through its out-patient department. She further said that in terms of medical treatment, ICU facilities, admission system and the dedication of doctors, AIIMS ranked among the country's top institutions. Gupta also planted a sapling on the AIIMS campus marking World Environment Day. She described this initiative as a vital part of Delhi govt's Harit campaign. While stressing that Delhi govt would plant 70 lakh saplings this year, Gupta urged the citizens to join the initiative in their areas and turn it into a people's movement.
Time of India
an hour ago
- Time of India
KEM 1st govt hosp to get adult marrow transplant
Mumbai: Nearly a year after a proposal was first made by BMC, KEM Hospital received official approval to establish a bone marrow transplant (BMT) centre. This will be the first such facility at a public hospital in Mumbai to serve both adults and children. Tired of too many ads? go ad free now BMT is a procedure that replaces damaged or diseased bone marrow with healthy stem cells that can come from the patient (autologous transplant) or a donor (allogeneic transplant). Hospital dean Dr Sangeeta Rawat inaugurated the site within the hospital premises where the new facility will be built. She said the centre will be funded through corporate social responsibility contributions, with treatment costs covered through a combination of donations and govt healthcare schemes. Construction is slated to begin soon, but it will take a year for the four-bed facility to be functional. The only other BMT in the city that covers adults is at Tata Memorial Hospital; but it is only for cancer patients. Dr Chandrakala S, who heads the haematology department at the hospital, said, "The need for BMT extends beyond cancer. It includes patients with aplastic anaemia, sickle cell disease, some autoimmune disorders, and even thalassemia major." She said most of such transplant centres are at private hospitals, and the costs can be upwards of Rs 10 lakh to Rs 12 lakh. "We see so many adult patients who need BMT, but cannot avail it only because there is no affordable facility in the city," she added.
Indian Express
an hour ago
- Indian Express
No CDSCO certificate, incomplete docs: Health dept orders inquiry over irregularities in medical equipment purchase
Maharashtra's Public Health Department has directed the Maharashtra Medical Goods Procurement Authority (MMGPA) to probe and submit a report on the alleged irregularities in awarding tenders of Rs 56 crore for the purchase of medical equipment. The allegations against the tender process involve that of financial irregularity as well as violating the administrative proceedings to favour select contractors. Earlier this year, the MMGPA had floated a tender to procure essential medical equipment like cell counter, microscope, lab autoclave, haemoglobin meter, haemoglobin strips, lithotomy table and lamp. A total of 5 companies participated in this tender, out of which only 2 were qualified. A complaint has been submitted with the Public Health department which alleges, CDSCO (Central Drug Standards Control Organisation) certificate was not submitted for medical equipment like autoclave and microscope, even though it was mandatory and tenders were awarded despite incomplete documents. It has been alleged that both the qualified bidders are authorised by the same manufacturing company. 'This is a direct violation of the Indian Competition Act 2002 and Tender Rule 2.2.6 (Conflict of Interest). Both the qualified tenderers did not attach the required documents such as work experience, customer testimonials and official tender documents signed by a chartered accountant to prove completion of the work worth Rs 28 crore (mandatory turnover value). The complaint has also mentioned that over all these tender irregularities, one ineligible bidder had duly registered objections with the Health Appeals Department and the Directorate of Industries office. 'However, without properly resolving these objections and doubts, the price envelope was opened in a hurry and the ineligible bidder was qualified and given a work order and a contract. This action clearly shows the complete lack of transparency in the tender process,' the complaint said. The public health department on June 4 asked MMGPA to undertake detailed inquiry into the objections raised against the tender process and submit the report at the earliest.
